Corrigendum to “Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme” [Int. J. Infect. Dis. 97 (2020) 182–189]

Abstract Background: In May 2018, the monovalent MenC-TT conjugate vaccine given at 14 months of age within the National Immunization Programme in the Netherlands was replaced by a 4-valent MenACWY-TT conjugate vaccine. Methods: Results from a questionnaire about local reactions and systemic events within 4 days after vaccination were compared with data from a comparable tolerability study of a monovalent MenC-TT vaccine. Results: The response rate was 5.5% (1157/20966 questionnaires). Any local reaction was reported for 3.7% of the toddlers, with the highest percentage found for local redness at the injection site (2.9%). Any systemic event was reported for 32.4% of the toddlers, with listlessness (22.4%) most often reported. Fever was the only symptom more frequently reported after MenACWY-TT vaccination compared with MenC-TT vaccination (adj OR 1.61; 95% CI 1.29-2.01).Conclusions: the 4-valent MenACWY-TT vaccine showed to be a little more reactogenic compared with to the monovalent MenC-TT vaccine, with a higher risk of fever within 4 days after vaccination. For the other factors no increased risks were found. Overall, this study shows that MenACWY-TT vaccination is well tolerated in toddlers.

Download Full-text

Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011–2018

PLoS ONE ◽

10.1371/journal.pone.0250010 ◽

2021 ◽

Vol 16 (4) ◽

pp. e0250010

Author(s):

John Njuma Libwea ◽

Mark A. Fletcher ◽

Paul Koki Ndombo ◽

Angeline Boula ◽

Nadesh Taku Ashukem ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Pneumococcal Meningitis ◽

Dose Schedule ◽

Population Based ◽

Immunization Programme ◽

Purulent Meningitis ◽

National Immunization Programme ◽

Wbc Count ◽

The Impact

Background The 13-valent pneumococcal conjugate vaccine (PCV13) entered Cameroon’s childhood national immunization programme (NIP) in July 2011 under a 3-dose schedule (6, 10, 14 weeks of age) without any catch-up. We described the impact of PCV13 onserotype distribution among pneumococcal meningitis cases over time. Methods We used laboratory-based sentinel surveillance data to identify meningitis cases among 2- to 59-month-old children with clinically-suspected bacterial meningitis (CSBM) admitted to hospitals in Yaoundé (August 2011-December 2018). Purulent meningitis cases had a cerebrospinal fluid (CSF) white blood cell (WBC) count ≥20 per mm3. Pneumococcal meningitis cases had S. pneumoniae identified from CSF, with serotyping by polymerase chain reaction. Years 2011-2014 were described as early PCV13 era (EPE) and years 2015-2018 as late PCV13 era (LPE) impact periods. Results Among children hospitalized with CSBM who had a lumbar puncture obtained, there was no significant change from the EPE versus the LPE in the percentage identified with purulent meningitis: 7.5% (112/1486) versus 9.4% (154/1645), p = 0.0846. The percentage of pneumococcal meningitis cases due to PCV13 vaccine-serotype (VST) decreased from 62.0% (31/50) during the EPE to 35.8% (19/53) in the LPE, p = 0.0081. The most frequent pneumococcal meningitis VSTs during the EPE were 6A/6B (30%) and 5 (6%), and during the LPE were 14 (13.2%), 3 (7.6%), 4 (5.6%) and 18C (5.6%). Conclusion Four to seven years after PCV13 introduction, the proportion of pneumococcal meningitis due to vaccine serotypes has declined, mainly due to reductions of serotypes 6A/6B, 1, 19A, and 23F; nevertheless, PCV13 VSTs remain common. Because the analyzed surveillance system was not consistent or population based, we could not estimate incidence or overall impact; this emphasizes the need for improved surveillance to document further the utility of PCV13 immunization in Cameroon.

Download Full-text